BTG makes progress

Specialist pharmaceutical group BTG (BTG) saw its shares rise 9 per cent on the back of these robust looking half-year figures - indeed, add back acquisition adjustments and reorganisation costs, and underlying operating profits rose 45 per cent to £59.5m. Moreover, strong cash flow from its existing drugs should support new product development.

visible-status-Subscription-Only story-url-BTG_result_081112.xml